An intellectual property obstacle nearly terminated the bivalirudin project. This constraint forced the team to devise a novel "bivalent" molecule, which not only bypassed the patent issue but also resulted in a more potent drug. This illustrates how external limitations can unexpectedly trigger superior innovation.
Related Insights
Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.
An acquisition earn-out prevented a founder from starting another competitive tech company. This constraint forced him out of his comfort zone and into exploring unfamiliar areas like podcasting. The limitation became a catalyst for innovation, leading him to a new, highly successful business model he wouldn't have otherwise considered.
The GSK3 inhibitor was developed for CNS diseases, requiring high specificity and the ability to cross the blood-brain barrier. These same pharmaceutical characteristics—potency and lipophilicity—proved highly advantageous for treating cancer, demonstrating an unexpected but effective therapeutic pivot from neuroscience to oncology.
Luba Greenwood reframes competition in biotech as a positive force. When multiple companies pursue the same biological target, it validates the target's importance and accelerates discovery. This collaborative mindset benefits the entire field and, ultimately, patients, as the best and safest drug will prevail.
A significant number of Eli Lilly's compelling inventions came from unsanctioned projects. The company intentionally provides budget flexibility and avoids micromanagement at its R&D sites, allowing scientists to pursue their curiosity.
The blockbuster drug bivalirudin was discovered as an unsanctioned "20% time" project at Biogen. This policy, allowing scientists to explore personal interests, demonstrates how institutionalizing freedom for undirected research can lead to major, company-defining breakthroughs that would otherwise be missed in a rigid R&D structure.
Instead of patenting a specific molecule, Alt-Pep underwent a decade-long process to patent the novel alpha-sheet protein structure itself. This unconventional IP strategy gives them a powerful, defensible platform applicable across numerous amyloid diseases, not just a single target composition.
Faced with China's superior speed and cost in executing known science, the U.S. biotech industry cannot compete by simply iterating faster. Its strategic advantage lies in
Many innovative drug designs fail because they are difficult to manufacture. LabGenius's ML platform avoids this by simultaneously optimizing for both biological function (e.g., potency) and "developability." This allows them to explore unconventional molecular designs without hitting a production wall later.
Contrary to the idea of limitless brainstorming, true innovation accelerates when leaders define clear boundaries. As seen in Lego's turnaround, providing constraints challenges teams to develop more focused, creative, and profitable solutions within a limited space.
